Gestasyonel Diyabette Plazma Ürotensin II Konsantrasyonu

Öz

Amaç: Urotensin II (UII) ve sistemi, birçok hastalığın (diyabet dahil) etyolojisinde rol oynar. Bu çalışmada gestasyonel diabetes mellitusta (GDM) UII'yi değerlendirmek ve karşılaştırmayı denedik.

Yöntemler: Çalışmaya alınan otuzaltı gebe (GDM olmayan 15 kadın hasta 1. Grubu ve 21 GDM kadın hasta 2. Grubu  oluşturdu). Üçüncü grup, yaşları eşleştirilmiş 22 gebe olmayan sağlıklı bireyden oluşuyordu. Plazma UII seviyeleri çalışmanın başında belirlendi. Doğum sonrası 12.hafta ikinci bir plazma UII düzeyi grup 1 ve 2 'deki hastalardan ölçüldü.

Bulgular: Hem GDM hem de GDM olmayan deneklerin Gestasyonel UII düzeyleri, gebe olmayan sağlıklı kontrollere göre daha yüksekti (her ikisi için p=0,0001). GDM'li hastaların gestasyonel ve postpartum UII düzeyleri, GDM'li olmayan gebelere göre daha yüksekti ancak istatistiksel olarak anlamlı değildi (p≥0.05). GDM'li olmayan kişilerde plazma UII konsantrasyonları, doğumdan sonra anlamlı olarak azaldı, ancak GDM'li kişilerde değişmedi (sırasıyla, p=0,036 ve p ≥0.05).

Sonuç: GDM hastalarında doğumdan sonra anlamlı bir şekilde azalmayan plazma UII konsantrasyonlarının yüksek bulunması (GDM olmayan bireylerle karşılaştırıldığında), UII'nin ve sisteminin GDM patogenezinde rol oynayabileceğini göstermektedir. Bu alanda daha ayrıntılı çalışmalara ihtiyaç vardır.

Anahtar Kelimeler

• ürotensin,gestasyonel diabet,gebelik,glukoz tolerans testi

Plasma Urotensin II Concentration In Gestational Diabetes

Abstract

Aim: Urotensin II (UII) and its system is implicated in the etiology of many diseases (including diabetes mellitus). We tried in this study to evaluate and compare UII levels in gestational diabetes mellitus (GDM).

Methods: Thirty-six pregnant women (15 non-GDM patients consisted group 1 and 21 GDM patients consisted group 2) enrolled in this study. The 3rd group consisted of age matched 22 non pregnant healthy women. Plasma UII levels were determined at the beginning of the study. After 12 weeks of delivery, a second plasma UII was determined from group 1 and 2.

Results: Gestational UII levels of both GDM and non-GDM patients were higher than non-pregnant healthy controls (p=0.0001 for both). Both gestational and postpartum UII levels of GDM patients were higher than non-GDM patients but had not reached statistical significance (P≥0.05). Plasma UII concentrations in non-GDM patients significantly decreased after delivery but not in GDM patients (p=0.036 and p≥0.05, respectively).

Conclusion: The finding of elevated gestational plasma UII concentrations in GDM patients which did not decrease significantly after delivery (in compare to non-GDM patients) shows that plasma UII levels may have a role in the pathogenesis of GDM. Further detailed studies are needed in this field.

Keywords

• urotensin,gestational diabetes,pregnancy,glucose tolerance test

Kaynakça

1. 1. Watanabe T, Kanome T, Miyazaki A, Katagiri T. Human urotensin II as a link between hypertension and coronary artery disease. Hypertension research : official journal of the Japanese Society of Hypertension. 2006;29(6):375-87. doi: 10.1291/hypres.29.375. PubMed PMID: 16940699.
2. 2. Dai HY, Guo XG, Ge ZM, Li ZH, Yu XJ, Tang MX, et al. Elevated expression of urotensin II and its receptor in diabetic cardiomyopathy. Journal of diabetes and its complications. 2008;22(2):137-43. doi: 10.1016/j.jdiacomp.2006.10.008. PubMed PMID: 18280445.
3. 3. Ong KL, Wong LY, Cheung BM. The role of urotensin II in the metabolic syndrome. Peptides. 2008;29(5):859-67. doi: 10.1016/j.peptides.2007.06.003. PubMed PMID: 17610998.
4. 4. Gruson D, Rousseau MF, Ketelslegers JM, Hermans MP. Raised plasma urotensin II in type 2 diabetes patients is associated with the metabolic syndrome phenotype. Journal of clinical hypertension. 2010;12(8):653-60. doi: 10.1111/j.1751-7176.2010.00336.x. PubMed PMID: 20695946.
5. 5. Tian L, Li C, Qi J, Fu P, Yu X, Li X, et al. Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-beta1-mediated renal fibrosis and dysfunction. American journal of physiology Endocrinology and metabolism. 2008;295(5):E1234-42. doi: 10.1152/ajpendo.90672.2008. PubMed PMID: 18796544.
6. 6. Marco J, Egido EM, Hernandez R, Silvestre RA. Evidence for endogenous urotensin-II as an inhibitor of insulin secretion. Study in the perfused rat pancreas. Peptides. 2008;29(5):852-8. doi: 10.1016/j.peptides.2007.08.025. PubMed PMID: 17931748.
7. 7. Cheung K, Wong S. Gestational diabetes mellitus update and review of literature. Reproductive Sys Sexual Disord S. 2012;2:002.
8. 8. Al-Noaemi MC, Shalayel MHF. Pathophysiology of Gestational Diabetes Mellitus: The Past, the Present and the Future. Gestational Diabetes. 2011:91.

9. 9. Tan YJ, Fan ZT, Yang HX. [Role of urotensin II gene in the genetic susceptibility to gestational diabetes mellitus in northern Chinese women]. Zhonghua fu chan ke za zhi. 2006;41(11):732-5. PubMed PMID: 17327028.
10. 10. International Association of D, Pregnancy Study Groups Consensus P, Metzger BE, Gabbe SG, Persson B, Buchanan TA, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes care. 2010;33(3):676-82. doi: 10.2337/dc09-1848. PubMed PMID: 20190296; PubMed Central PMCID: PMC2827530.
11. 11. Hursitoglu M, Tukek T, Cikrikcioglu MA, Kara O, Kazancioglu R, Ozkan O, et al. Urotensin II levels in patients with chronic kidney disease and kidney transplants. Upsala journal of medical sciences. 2012;117(1):22-7. doi: 10.3109/03009734.2011.626541. PubMed PMID: 22098077; PubMed Central PMCID: PMC3282238.
12. 12. Balat O, Aksoy F, Kutlar I, Ugur MG, Iyikosker H, Balat A, et al. Increased plasma levels of Urotensin-II in preeclampsia-eclampsia: a new mediator in pathogenesis? European journal of obstetrics, gynecology, and reproductive biology. 2005;120(1):33-8. doi: 10.1016/j.ejogrb.2004.07.029. PubMed PMID: 15866083.
13. 13. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011;22(5):1170-80. doi: 10.1093/annonc/mdq583. PubMed PMID: 21115603; PubMed Central PMCID: PMC3082161.
14. 14. Cowley E, Thompson JP, Sharpe P, Waugh J, Ali N, Lambert DG. Effects of pre-eclampsia on maternal plasma, cerebrospinal fluid, and umbilical cord urotensin II concentrations: a pilot study. British journal of anaesthesia. 2005;95(4):495-9. doi: 10.1093/bja/aei222. PubMed PMID: 16126783.
15. 15. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clinical science. 2003;104(1):1-5. doi: 10.1042/. PubMed PMID: 12519081.
16. 16. Silvestre RA, Egido EM, Hernandez R, Leprince J, Chatenet D, Tollemer H, et al. Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas. European journal of endocrinology / European Federation of Endocrine Societies. 2004;151(6):803-9. PubMed PMID: 15588249.
17. 17. Hansen L, Hartmann B, Bisgaard T, Mineo H, Jorgensen PN, Holst JJ. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. American journal of physiology Endocrinology and metabolism. 2000;278(6):E1010-8. PubMed PMID: 10827002.
18. 18. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. 2001;25(6):781-92. doi: 10.1038/sj.ijo.0801627. PubMed PMID: 11439290.
19. 19. Kalra B, Gupta Y, Singla R, Kalra S. Use of oral anti-diabetic agents in pregnancy: a pragmatic approach. North American journal of medical sciences. 2015;7(1):6-12. doi: 10.4103/1947-2714.150081. PubMed PMID: 25709972; PubMed Central PMCID: PMC4325398.
20. 20. Ng MT. Effects of prominsulin C-peptide and other islet peptides on beta-cell function and insulin secretion: University of Ulster; 2011.
21. 21. O'Harte FP, Abdel-Wahab YH, Conlon JM, Flatt PR. Glycation of glucagon-like peptide-1(7-36)amide: characterization and impaired action on rat insulin secreting cells. Diabetologia. 1998;41(10):1187-93. doi: 10.1007/s001250051050. PubMed PMID: 9794106.